AMAG Pharmaceuticals, Inc. (AMAG)
-NasdaqGS 24.93 
0.44(1.73%) 4:00PM EDT|After Hours
:
24.93 0.00 (0.00%) 4:23PM EDT
| Prev Close: | 25.37 |
|---|
| Open: | 25.21 |
|---|
| Bid: | N/A |
|---|
| Ask: | 45.00 x 400 |
|---|
| 1y Target Est: | 22.14 |
|---|
| Beta: | 0.27 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 24.54 - 25.28 |
|---|
| 52wk Range: | 12.98 - 25.67 |
|---|
| Volume: | 206,292 |
|---|
| Avg Vol (3m): | 134,477 |
|---|
| Market Cap: | 537.84M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.38 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AMAG July Options Begin Tradingat Forbes(Mon 2:52PM EDT)
- AMAG PHARMACEUTICALS INC. FinancialsEDGAR Online Financials(Fri, May 10)
- Ferumoxytol Results in Significant Hemoglobin Increases in Adult Iron Deficiency Anemia Patients With Abnormal Uterine Bleeding Who Had Failed or Could Not Tolerate Oral Iron TherapyGlobeNewswire(Mon, May 6)
- AMAG PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Sun, May 5)
- AMAG Pharmaceuticals to Present at the Needham Healthcare ConferenceBusiness Wire(Fri, Apr 26)
- Turkish Assets, Danish Triggers, Hedge Funds: Complianceat Bloomberg(Fri, Apr 26)
- AMAG Narrows Loss; Maintains ViewZacks(Wed, Apr 24)
- AMAG Pharmaceuticals' CEO Discusses Q1 2013 (Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 23)
- AMAG Pharmaceuticals Earnings: Here’s Why Investors Like These Resultsat Wall St. Cheat Sheet(Tue, Apr 23)
- AMAG Pharmaceuticals, Inc. Earnings Call scheduled for 4:30 pm ET todayCCBN(Tue, Apr 23)
- AMAG Announces First Quarter 2013 Financial ResultsBusiness Wire(Tue, Apr 23)
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements andEDGAR Online(Tue, Apr 23)
- Q1 2013 AMAG Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Tue, Apr 23)
- AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013Business Wire(Fri, Apr 19)
- AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Apr 4)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.24 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.63 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | -0.57 |
|---|
Business Summary
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA).
View More